Monoclonal Antibodies in Prevention and Early Treatment of COVID-19 in Lung Transplant Recipients: A Systematic Review and Perspective on the Role of Monoclonal Antibodies in the Future
Coronavirus disease 2019 (COVID-19) has significantly impacted lung transplant recipients (LTR), who remain vulnerable to severe COVID-19 despite vaccination, prompting the use of monoclonal antibodies (mAbs) as a treatment option. This systematic review summarizes the clinical efficacy of mAbs agai...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Transplant International |
| Subjects: | |
| Online Access: | https://www.frontierspartnerships.org/articles/10.3389/ti.2025.13800/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823860009039036416 |
|---|---|
| author | David A. Van Eijndhoven Robin Vos Robin Vos Saskia Bos Saskia Bos |
| author_facet | David A. Van Eijndhoven Robin Vos Robin Vos Saskia Bos Saskia Bos |
| author_sort | David A. Van Eijndhoven |
| collection | DOAJ |
| description | Coronavirus disease 2019 (COVID-19) has significantly impacted lung transplant recipients (LTR), who remain vulnerable to severe COVID-19 despite vaccination, prompting the use of monoclonal antibodies (mAbs) as a treatment option. This systematic review summarizes the clinical efficacy of mAbs against COVID-19 in adult LTR and provides a perspective on the role of mAbs for infectious diseases in the future. A systematic search of PubMed/MEDLINE, Embase and Cochrane was conducted for studies reporting clinical outcomes of adult LTR or solid organ transplant recipients (SOTR) including LTR with drug-specific outcomes. Twelve studies were included. Pre-exposure prophylaxis with mAbs reduced COVID-19 breakthrough infection in LTR. Early treatment of COVID-19 with mAbs correlated with a reduced incidence of severe COVID-19 outcomes, although statistical significance varied among studies. Overall, observational studies have demonstrated a potential benefit of mAbs in the treatment of COVID-19 in LTR, both in prophylaxis and early treatment, as well as the importance of early administration. Moreover, mAb therapy appeared safe and could be a viable option against other pathogens, a route that warrants further investigation.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?RecordID=382133, identifier CRD42022382133. |
| format | Article |
| id | doaj-art-d23a4bb0926e435f8c08b2151019ade6 |
| institution | Kabale University |
| issn | 1432-2277 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Transplant International |
| spelling | doaj-art-d23a4bb0926e435f8c08b2151019ade62025-02-10T17:07:12ZengFrontiers Media S.A.Transplant International1432-22772025-02-013810.3389/ti.2025.1380013800Monoclonal Antibodies in Prevention and Early Treatment of COVID-19 in Lung Transplant Recipients: A Systematic Review and Perspective on the Role of Monoclonal Antibodies in the FutureDavid A. Van Eijndhoven0Robin Vos1Robin Vos2Saskia Bos3Saskia Bos4Medical School, Catholic University Leuven, Leuven, BelgiumDepartment of Respiratory Medicine, University Hospitals Leuven, Leuven, BelgiumDepartment of CHROMETA, Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE), KU Leuven, Leuven, BelgiumDepartment of Respiratory Medicine, University Hospitals Leuven, Leuven, BelgiumDepartment of CHROMETA, Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE), KU Leuven, Leuven, BelgiumCoronavirus disease 2019 (COVID-19) has significantly impacted lung transplant recipients (LTR), who remain vulnerable to severe COVID-19 despite vaccination, prompting the use of monoclonal antibodies (mAbs) as a treatment option. This systematic review summarizes the clinical efficacy of mAbs against COVID-19 in adult LTR and provides a perspective on the role of mAbs for infectious diseases in the future. A systematic search of PubMed/MEDLINE, Embase and Cochrane was conducted for studies reporting clinical outcomes of adult LTR or solid organ transplant recipients (SOTR) including LTR with drug-specific outcomes. Twelve studies were included. Pre-exposure prophylaxis with mAbs reduced COVID-19 breakthrough infection in LTR. Early treatment of COVID-19 with mAbs correlated with a reduced incidence of severe COVID-19 outcomes, although statistical significance varied among studies. Overall, observational studies have demonstrated a potential benefit of mAbs in the treatment of COVID-19 in LTR, both in prophylaxis and early treatment, as well as the importance of early administration. Moreover, mAb therapy appeared safe and could be a viable option against other pathogens, a route that warrants further investigation.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?RecordID=382133, identifier CRD42022382133.https://www.frontierspartnerships.org/articles/10.3389/ti.2025.13800/fulllung transplantationCOVID-19Sars-CoV-2monoclonal antibodiestixagevimab/cilgavimabsotrovimab |
| spellingShingle | David A. Van Eijndhoven Robin Vos Robin Vos Saskia Bos Saskia Bos Monoclonal Antibodies in Prevention and Early Treatment of COVID-19 in Lung Transplant Recipients: A Systematic Review and Perspective on the Role of Monoclonal Antibodies in the Future Transplant International lung transplantation COVID-19 Sars-CoV-2 monoclonal antibodies tixagevimab/cilgavimab sotrovimab |
| title | Monoclonal Antibodies in Prevention and Early Treatment of COVID-19 in Lung Transplant Recipients: A Systematic Review and Perspective on the Role of Monoclonal Antibodies in the Future |
| title_full | Monoclonal Antibodies in Prevention and Early Treatment of COVID-19 in Lung Transplant Recipients: A Systematic Review and Perspective on the Role of Monoclonal Antibodies in the Future |
| title_fullStr | Monoclonal Antibodies in Prevention and Early Treatment of COVID-19 in Lung Transplant Recipients: A Systematic Review and Perspective on the Role of Monoclonal Antibodies in the Future |
| title_full_unstemmed | Monoclonal Antibodies in Prevention and Early Treatment of COVID-19 in Lung Transplant Recipients: A Systematic Review and Perspective on the Role of Monoclonal Antibodies in the Future |
| title_short | Monoclonal Antibodies in Prevention and Early Treatment of COVID-19 in Lung Transplant Recipients: A Systematic Review and Perspective on the Role of Monoclonal Antibodies in the Future |
| title_sort | monoclonal antibodies in prevention and early treatment of covid 19 in lung transplant recipients a systematic review and perspective on the role of monoclonal antibodies in the future |
| topic | lung transplantation COVID-19 Sars-CoV-2 monoclonal antibodies tixagevimab/cilgavimab sotrovimab |
| url | https://www.frontierspartnerships.org/articles/10.3389/ti.2025.13800/full |
| work_keys_str_mv | AT davidavaneijndhoven monoclonalantibodiesinpreventionandearlytreatmentofcovid19inlungtransplantrecipientsasystematicreviewandperspectiveontheroleofmonoclonalantibodiesinthefuture AT robinvos monoclonalantibodiesinpreventionandearlytreatmentofcovid19inlungtransplantrecipientsasystematicreviewandperspectiveontheroleofmonoclonalantibodiesinthefuture AT robinvos monoclonalantibodiesinpreventionandearlytreatmentofcovid19inlungtransplantrecipientsasystematicreviewandperspectiveontheroleofmonoclonalantibodiesinthefuture AT saskiabos monoclonalantibodiesinpreventionandearlytreatmentofcovid19inlungtransplantrecipientsasystematicreviewandperspectiveontheroleofmonoclonalantibodiesinthefuture AT saskiabos monoclonalantibodiesinpreventionandearlytreatmentofcovid19inlungtransplantrecipientsasystematicreviewandperspectiveontheroleofmonoclonalantibodiesinthefuture |